Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Unternehmen & Branche
| Name | Xeris Biopharma Holdings, Inc. |
|---|---|
| Ticker | XERS |
| CIK | 0001867096 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,04 Mrd. USD |
| Beta | 0,99 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 291,845,000 | 554,000 | 0.00 | 383,527,000 | 13,689,000 |
| 2025-09-30 | 10-Q | 74,380,000 | 621,000 | 0.00 | 370,191,000 | -861,000 |
| 2025-06-30 | 10-Q | 71,539,000 | -1,928,000 | -0.01 | 334,686,000 | -19,304,000 |
| 2025-03-31 | 10-Q | 60,119,000 | -9,220,000 | -0.06 | 315,453,000 | -35,128,000 |
| 2024-12-31 | 10-K | 203,070,000 | -54,836,000 | -0.37 | 323,060,000 | -29,615,000 |
| 2024-09-30 | 10-Q | 54,268,000 | -15,738,000 | -0.11 | 321,104,000 | -28,323,000 |
| 2024-06-30 | 10-Q | 48,065,000 | -15,005,000 | -0.10 | 331,733,000 | -19,286,000 |
| 2024-03-31 | 10-Q | 40,638,000 | -18,980,000 | -0.14 | 336,616,000 | -9,178,000 |
| 2023-12-31 | 10-K | 163,914,000 | -62,255,000 | -0.45 | 322,602,000 | -6,782,000 |
| 2023-09-30 | 10-Q | 48,320,000 | -12,189,000 | -0.09 | 327,784,000 | 3,865,000 |
| 2023-06-30 | 10-Q | 38,008,000 | -19,842,000 | -0.14 | 328,778,000 | 13,641,000 |
| 2023-03-31 | 10-Q | 33,196,000 | -16,834,000 | -0.12 | 321,360,000 | 30,048,000 |
| 2022-12-31 | 10-K | 110,248,000 | -94,660,000 | -0.70 | 344,522,000 | 45,187,000 |
| 2022-09-30 | 10-Q | 29,725,000 | -21,831,000 | -0.16 | 303,017,000 | 55,040,000 |
| 2022-06-30 | 10-Q | 25,306,000 | -26,185,000 | -0.19 | 318,616,000 | 73,943,000 |
| 2022-03-31 | 10-Q | 22,073,000 | -33,714,000 | -0.25 | 337,623,000 | 96,455,000 |
| 2021-12-31 | 10-K | 49,590,000 | -122,725,000 | -1.55 | 304,361,000 | 95,231,000 |
| 2021-09-30 | 10-Q | 11,060,000 | -26,009,000 | -0.39 | 131,260,000 | -2,461,000 |
| 2021-06-30 | 10-Q | 8,906,000 | -27,515,000 | -0.41 | 19,888,000 | |
| 2021-03-31 | 10-Q | 8,195,000 | -18,411,000 | -0.30 | 44,387,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Hecht Beth | Officer, See Remarks | Open Market Sale | -16,667 | 5.99 | -99,858.66 | -45,3% | |
| 2026-03-30 | Brady James Aloysius | Director | Open Market Sale | -10,834 | 5.54 | -60,035.53 | -27,3% | |
| 2026-03-02 | Hecht Beth | Officer, See Remarks | Open Market Sale | -16,567 | 6.24 | -103,379.74 | -46,9% | |
| 2026-03-02 | Hecht Beth | Officer, See Remarks | Open Market Sale | -100 | 7.06 | -706.00 | -0,3% | |
| 2026-02-02 | Hecht Beth | Officer, See Remarks | Open Market Sale | -16,667 | 7.45 | -124,147.48 | -56,4% | |
| 2026-01-08 | McCulloch Kevin | Officer, See Remarks | Open Market Sale | -15,000 | 8.00 | -120,000.00 | -54,5% | |
| 2026-01-05 | Shannon John Patrick Jr | Director, Officer, See Remarks | Open Market Sale | -24,907 | 7.08 | -176,256.88 | -80,0% | |
| 2026-01-02 | Hecht Beth | Officer, See Remarks | Open Market Sale | -16,667 | 7.43 | -123,775.81 | -56,2% | |
| 2025-12-19 | JOHNSON JOHN | Director | Open Market Sale | -135,400 | 7.22 | -977,019.32 | -443,6% | |
| 2025-12-12 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Open Market Sale | -15,000 | 7.09 | -106,414.50 | -48,3% | |
| 2025-12-01 | Hecht Beth | Officer, See Remarks | Open Market Sale | -16,667 | 7.01 | -116,780.67 | -53,0% | |
| 2025-11-13 | Shannon John Patrick Jr | Director, Officer, See Remarks | Open Market Sale | -23,242 | 7.46 | -173,401.59 | -78,7% | |
| 2025-11-11 | Hecht Beth | Officer, See Remarks | Open Market Sale | -16,667 | 7.40 | -123,295.80 | -56,0% | |
| 2025-09-11 | PERSKY MARLA | Director | Open Market Sale | -15,500 | 7.72 | -119,610.40 | -54,3% | |
| 2025-08-28 | SHERMAN JEFFREY W | Director | Open Market Sale | -42,232 | 7.92 | -334,515.45 | -151,9% | |
| 2025-08-13 | JOHNSON JOHN | Director | Open Market Sale | -107,500 | 7.32 | -786,459.25 | -357,1% | |
| 2025-08-12 | HALKUFF DAWN | Director | Open Market Sale | -42,500 | 7.28 | -309,225.75 | -140,4% | |
| 2025-06-13 | McCulloch Kevin | Officer, See Remarks | Open Market Purchase | 25,000 | 4.38 | 109,475.00 | +49,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.